Rtw Biotech Opportunities Share Discussion Threads

[rambutan2] 03/10/2024 15:53

But smid US biotech remains becalmed for the time being:

[rambutan2] 03/10/2024 15:40

Also had an IPO and another new investment over the last couple of weeks:

[rambutan2] 03/10/2024 15:38

Their play on a huge, albeit currently very competitive, mkt:

Roderick Wong, Managing Partner and CIO at the Investment Manager commented on the launch, "We are immensely proud to co-lead the Series A launch of Kailera Therapeutics, our fourth new company creation at RTW. Kailera represents a significant step forward in addressing the huge market for chronic weight management and metabolic diseases. With its clinically-validated pipeline and experienced management team, we are confident that Kailera is well-positioned to develop breakthrough therapies that will profoundly improve the lives of patients worldwide. We look forward to supporting them on this transformative journey."

[rambutan2] 15/9/2024 22:00

Interim report, released on fri, is a good read, with some interesting portfolio details:

[affemoose] 25/7/2024 14:09

This is a great little stock imho. Just wish i'd bought more :-)

I love teh exposure to early stage assets - this is key for me. It's a roller coaster but the skill set of the management is great and I am buying because i believe that they know what they are doing and can load the dice in RTW's favour when it comes to early stage Pharma/Biotech. The potential rewards are high. As of course, are the losses. Hence my investment in the people.

[rambutan2] 16/7/2024 19:45

End of quarter update etc. Still on sale on a 20% discount and in a still beaten down sector...

[makinbuks] 14/6/2024 16:35

Been very pleased with how things have gone here since I came in via the Arix . Hopefully a great deal more to come

[affemoose] 11/6/2024 11:06

Investment Subsid' sale - $4.5m for RTW

hxxps://www.marketscreener.com/quote/stock/RTW-BIOTECH-OPPORTUNITIES-74010978/news/RTW-Biotech-portfolio-company-to-sell-subsidiary-for-USD1-25-billion-46946614/

[eaaxs06] 08/5/2024 11:35

A nice buy has just gone through, 255k @ 1.36. Lets hope there are more to come.Good luck everyone, Sid.

[rambutan2] 07/4/2024 18:39

Latest addition to the unquoted port via a "significantly oversubscribed" $160m C round:

[makinbuks] 28/3/2024 11:13

Yes I agree Post balance sheet events focused only on completed transactions and some general market commentary. We'll get another factsheet in about two weeks.

The number of holdings is quite small. I wonder if they will sell some Avidity to avoid over concentration. These are the problems we want to be talking about !

[rimau1] 28/3/2024 07:21

Results out as expected nothing new particularly even in the 2024 outlook. However at the AGM in May there will be a 2024 portfolio update and shareholder Q&A.

[rimau1] 27/3/2024 15:56

Avidity up another 6percent today or 67percent since end Feb. Now that is interesting...

[makinbuks] 26/3/2024 18:01

True, but the commentary can be interesting and "as of" the date of publication

[rimau1] 26/3/2024 17:33

Results y/e 31Dec on or around Thursday 28th March. Still pre Axis so potentially not very interesting given we get a monthly factsheet

[rambutan2] 26/3/2024 14:04

Apogee was 2% of nav at end of jan, but in feb the Arix assets joined so all percentages changed.

Avidity was 1.9% at end of jan. So they must have bought in big time in feb, likely as an insider in the fund raising at $16.50.

I think the y/e results are out this week or next. Will be interesting to hear what they've got to say.

[makinbuks] 25/3/2024 17:12

Avidity is up 26% from the end of Feb, and was 9% of the fund

Apogee is up 94% since Feb, not clear how material to NAV that holding is, could be c.1% (last stated position I can find is 0.6% last June which was at IPO)

And they've bought back 2.25m shares in March or 0.6%

Discount around 33% at this level

[rambutan2] 23/3/2024 20:39

Apogee (APGE) is another big, up 50%, riser this month on the back of trial news and subsequent raise. RTW was a backer from pre IPO at multiples lower.

[rambutan2] 21/3/2024 22:09

Yes, very wrongly priced currently. The sector trades on around a 10% discount, so this has got really out of wack. And especially so considering it is a top performer and has a quality manager. It offers a rare opportunity to buy a real no brainer. imho.

Sector stats:


I note that in the last fact sheet, Avidity came from nowhere to be 9% of nav. Since then, it is up approx 40% on good news and a fund raise in which RTW participated. This just illustrates one of the great advantages offered by being part of the RTW platform, one of the elite bio investors in the States.

[rimau1] 14/3/2024 10:37

Discount is much too wide here, accretive buybacks and plenty of cash, 1.40 looks about right in the short term.

[ntv] 14/3/2024 08:32

Increase of 5c since last update
A couple of larger holdings have been on the move since the end of Feb

[ntv] 08/3/2024 07:53

Cargo T going for open sky

[rimau1] 21/2/2024 19:10

Its a good question, not really small single digit accretive was it!! They have set out all the reasons why a downward revision could have occurred since 31 Jan. Most likely is that they have now applied the RTW valuation methodology to the Arix privately held assets. I also think the the Jan 31 NAV of $1.94 was artificially high since it included the 25.5% stake in Axis that they had purchased for £1.37 which was worth £1.44 at 31 Jan. Just a guess.

[jaf111] 21/2/2024 15:10

Agree that it certainly looks attractive but have to admit being very disappointed with the $1.88 proforma number.
When the “merger” was announced last November RTW stated it was expected to be immediately accretive to RTW NAV per share……
But the end Jan (pre merger) NAV was $1.94 per share……..
Have I missed something??????